Aca­dia shares slide — again — af­ter FDA con­firms it has launched a safe­ty re­view of Nu­plazid

Aca­dia’s suf­fer­ing shares $ACAD took an­oth­er hit on Wednes­day, plung­ing 22% af­ter the FDA con­firmed to­day that reg­u­la­tors have be­gun a re­view of its an­ti-psy­chosis drug Nu­plazid — fol­low­ing CNN’s re­port ques­tion­ing the safe­ty of the drug.

A ’break­through’ drug ush­ered in­to the mar­ket to treat Parkin­son’s dis­ease psy­chosis, CNN re­cent­ly high­light­ed a non­prof­it’s warn­ing on 244 deaths in­volv­ing pa­tients on the drug in less than a year af­ter its launch. Aca­dia re­spond­ed by say­ing there’s no rea­son to be­lieve the drug was di­rect­ly re­spon­si­ble for any of the deaths CNN spot­light­ed in its sto­ry. And the FDA not­ed at the time that there is no rea­son to be­lieve there is any safe­ty is­sue that isn’t al­ready cov­ered by the la­bel. 

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.